Evotec Stock
Evotec SE
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Germany
- CEO
- Christian Wojczewski
- Employees
- 4,553
- Market cap
- $490 M
- IPO
- 05/02/2004
Evotec SE operates globally as a dedicated partner specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders including…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Evotec stock: price history
1D
-2.8%
1W
-9.8%
1M
-15.3%
6M
-57.7%
YTD
-55.2%
1Y
-65.5%
2Y
-54.2%
5Y
-93.9%
10Y
-50.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~38% stronger price swings than usual
Ask the agents about Evotec
Analyst assessment of Evotec
PRICE TARGET LOW
US$2.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
4
BUY
3
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 14/10/2026
Evotec stock metrics
P/E
-2.32
P/B
0.69
EV/EBITDA
-20.93
RETURN ON EQUITY
-7.1%
NET MARGIN
-32.5%
DEBT/EQUITY
0.71
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.8%
FLOAT SHARES
336,819,904
AVG. DAILY VOLUME (30D)
158,101
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.8%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Evotec stock
What does Evotec do?
Evotec SE is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Germany.
The CEO is Christian Wojczewski, the company employs around 4,553 people.
The IPO was on 05/02/2004; the stock trades on NASDAQ under the ticker EVO.
What do analysts say about Evotec stock?
7 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$3.00, ranging from US$2.00 to US$4.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Evotec report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 38% stronger than usual.
Does Evotec pay a dividend?
Yes. The last dividend was US$0.29 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Evotec?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Evotec stock analyzed?
Clicking "Analyze stock" lets five strategies assess Evotec against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.